| 胡 芝,徐 律,黄一统.多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的临床疗效分析[J].肿瘤学杂志,2014,20(10):829-832. |
| 多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的临床疗效分析 |
| Clinical Efficacy of Docetaxel Combined with Nedaplatin Chemotherapy Concurrent with Radiotherapy for Advanced Cervical Cancer |
| 投稿时间：2014-06-13 |
| DOI：10.11735/j.issn.1671-170X.2014.10.B010 |
|
 |
| 中文关键词: 宫颈肿瘤 多西他赛 奈达铂 同步放化疗 |
| 英文关键词:cervical neoplasms docetaxel nadaplatin concurrent radiochemotherapy |
| 基金项目: |
|
| 摘要点击次数: 2675 |
| 全文下载次数: 1043 |
| 中文摘要: |
| 摘 要：［目的］ 探讨多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的临床疗效。［方法］ 96例中晚期宫颈癌患者分为单纯放射治疗组(48例)和同步放化疗组(48例，给予多西他赛联合奈达铂化学治疗，同时给予放射治疗)，对两组病例的近期疗效、局部复发率、远处转移率、1年生存率、2年生存率和不良反应进行对比分析。［结果］ 单纯放射治疗组和同步放化疗组治疗的有效率分别为72.9%和95.8%，两组比较差异有统计学意义(χ2＝9.56，P＜0.05)；同步放化疗组1年生存率97.9%、2年生存率93.8%明显高于单纯放疗组83.3%和79.2%，两组比较差异有统计学意义(χ2＝4.41， χ2＝4.36，P＜0.05)；同步放化疗组局部复发率（4.2%）及远处转移率（4.2%）明显低于单纯放疗组25.0%和20.8%（χ2＝8.36， χ2＝6.10，P＜0.05)；同步放化疗组和单纯放射治疗组的近期不良反应均以骨髓抑制为主，前者高于后者，差异有统计学意义(P＜0.05)，但患者均能耐受。［结论］ 应用多西他赛联合奈达铂同步放化疗方案治疗中晚期宫颈癌患者临床疗效确切，患者耐受性较好，能够降低宫颈癌局部复发及远处转移率，明显改善患者生存率。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the clinical efficacy of docetaxel combined with nedaplatin chemotherapy concurrent with radiotherapy for advanced cervical cancer. ［Methods］ Ninety-six cases with advanced cervical cancer were divided into radiotherapy alone group (48 cases) and concurrent radiochemotherapy group(48 cases， docetaxel combined with nedaplatin chemotherapy concurrent with radiotherapy).The short-term response，local recurrence rate，distant metastatic rate，1- and 2-year survival rates ，and toxicities were compared between the two groups.［Results］ The short-term response rate in radiotherapy alone group and concurrent radiochemotherapy group was 72.9% and 95.8%，with significant difference(χ2＝9.56，P＜0.05). 1-year and 2-year survival rates in concurrent radiochemotherapy group (97.9 and 93.8%) were higher than those in radiotherapy alone group(83.3% and 79.2%) (χ2＝4.41， χ2＝4.36，P＜0.05). The local recurrence rate(4.2%) and distant metastatic rate(4.2%) in concurrent radiochemotherapy group were significantly lower than those in radiotherapy alone group (25.0%，20.8%)（χ2＝8.36， χ2＝6.10，P＜0.05). The main toxicity was bone marrow suppression which was higher in concurrent radiochemotherapy group than that in radiotherapy alone group(P＜0.05)，but it was tolerable. ［Conclusion］ Docetaxel combined with nedaplatin chemotherapy concurrent with radiotherapy is effective and tolerable for the treatment of advanced cervical cancer ， and can decrease the local recurrence rate and distant metastatic rate，and significantly improve the survival of the patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |